UCLA’s Beth Karlan receives IGCS’s lifetime achievement award

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Physician-scientist Beth Karlan, professor of obstetrics and gynecology in the David Geffen School of Medicine at UCLA and director of cancer population genetics at the UCLA Jonsson Comprehensive Cancer Center, has received the Lifetime Achievement Award from the International Gynecologic Cancer Society for her contributions to gynecologic cancer research and clinical practice. 

The award is bestowed annually.  

Karlan is being recognized for advancing the understanding of hereditary cancers and molecular drivers of ovarian cancer and her commitment in seeking better ways to prevent and eradicate deadly cancers.   

In the laboratory, Karlan has identified subtype-specific biomarkers for early detection, prognostication and personalized therapies. She established a human tissue biorepository to collect fresh frozen tissue, serum, and germline DNA from women with ovarian and other gynecologic cancers in order to study cancers’ biologic differences and develop improved treatments. 

This resource has been used in national and international collaborations including The Cancer Genome Atlas project, Consortium of Investigators of Modifiers of BRCA1/2 and Ovarian Cancer Association Consortium — partnerships that have helped to shape current standards of care for gynecologic oncology. 

She is also a co-PI on a national effort using a digital platform to implement population-based genetic testing for BRCA1 and BRCA2 mutations. 

The award will be presented to Karlan at the IGCS annual global meeting in Rome Sept. 1.

Table of Contents

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login